A national community-level study of Medicare patients with advanced non-small cell lung cancer found that adding targeted therapy to chemotherapy regimens was not cost-effective.
Janice N. Cormier, MD, MPH, FACS
Advertisement
Articles by Janice N. Cormier, MD, MPH, FACS
Advertisement
Latest Updated Articles
- Cost-Utility Analysis of Treatments for Advanced Non-Small Cell Lung Cancer
Published: January 6th 2016 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
A Review of Antibody-Drug Conjugates for the Treatment of Urothelial Carcinoma: The Rise of Enfortumab Vedotin
2
Oral Semaglutide Shows Promise for Weight Loss and Cardiometabolic Health
3
Interim Phase 2 IOV-LUNG-202 Data Show Lifileucel’s Potential Treating Advanced NSCLC
4
Low-Dose Aspirin Linked to Lower Cardiovascular Risk in Type 2 Diabetes
5
